univers coverag
calendar event
medacorp event post-op pain investor dinner discuss kol
pacira exparel heron new york
medic meet alzheim associ note wild ride ahead aaic
data could drive american societi retina specialist
intern aid societi societi neurointervent surgeri
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
someth go rightoption nhl trial
averag method dcf price earn price sale
bottom line celgen stock plagu tripl threat poor invest decis
weak oper perform long term patent uncertainti result one worst
perform stock larg cap biotech group last month investor
get modest boost one mani pipelin bet compani made offer investor
unpric option yesterday market close celgen announc augment trial revlimid
plu rituximab mainten line treatment relapsed/refractori indol lymphoma met
primari endpoint trial highest odd success compani cell malign
trial revlimid sharepric upsid augment like modest
posit result emphas option exist mani part compani pipelin despit
recent histori everyth compani portfolio fail everi oper result disappoint
pessim compani stock suggest opportun us option
mid- late stage pipelin signific reason behind continu outperform rate stock
despit mani develop oper stumbl last year
bottom line apo nr announc acquir lpnt friday close take
compani privat merg apo affili rcch takeout multipl ev/
ebitda consensu vs friday trade multipl acut group averag though
consensu reflect low-to-mid singl digit ebitda va medicaid expans rural-focus
rcch form merger regionalcar capella healthcar oper
region health system combin entiti greater revenu oper
non-urban hospit state view transact receiv anti-trust clearanc
minim divestitur lpnt chairman ceo william carpent lead combin compani
expect rcch chairman ceo martin rash cfo mike browder remain key role
integr compani apollo pursu reit strategi portion rcch hospit portfolio
convert reit own nr given lpnt favor leverag view
strategi may pursu lpnt solicit altern acquisit propos aug
transact expect close next sever month
gx kcl approv small posit opportun follow
bottom line morn amneal announc approv gener version potassium chlorid
oral solut mg per mg per ml per iqvia potassium chlorid oral solut
annual us sale last month end may note iqvia
sale belong endo op highlight product limit competit opportun
believ endo taken conserv approach guidanc particular limit competit
gener product otherwis exclus wouldnt surpris potassium chlorid oral
solut fell bucket amneal believ potassium chlorid oral solut
mean home run term new product launch type singl doubl opportun
manag allud get said look product launch
first mani amneal look hit ebitda guidanc year
better retain benefit pkd data derisk and
 methodolog dcf discount rate termin gr rate
bottom line morn report posit retain benefit data alport
syndrom patient enrol portion cardin studi better
expect link believ derisk result expect addit
report strong data patient autosom domin polycyst kidney diseas
adpkd much larger orphan kidney diseas opportun bardoxolon bard
view rais pt increas po alport syndrom
ad adpkd model probabl success po reiter
initi op novel mrna platform cystic fibrosi diseas pt
wacc termin growth rate
weekli iqvia im trend week end juli
updat
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
aug omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom aug
potenti approv oct time-frame could move stock meaning
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like late juli
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac ew
fda adcom joint meet drug safeti risk manag anesthet
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american societi retina specialist
alzheim associ note wild ride ahead aaic data
could drive
societi neurointervent surgeri
american associ physicist medicin
american associ clinic chemistri
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
deadlin lpnt solicit altern acquisit propos
go live az
model recent updat pleas contact leerink
repres wish review
biopharma preview gener pain women anti-infect
hcit distribut preview pocket opportun
medic suppli devic individu co preview cardio large-cap
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
note wild ride ahead aaic data could drive
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
 come-back stori make survey support opu market
share assumpt outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
